Organ Preservation Market by Solution (UW/Custodiol HTK/Perfadex), Technique (Static Cold Storage/Hypothermic Machine Perfusion/ Normothermic Machine Perfusion), Organ Type (Kidneys/Liver/Lungs/Heart), Region – Global Forecast to 2024

2020-02-10
Price :
Published : Feb-2020
No. of Pages : 140

“The organ preservation market is projected to grow at a CAGR of 6.5%.”

The global organ preservation market is projected to reach USD 284 million by 2024 from USD 207 million in 2019, at a CAGR of 6.5%. The growth of the organ preservation market is mainly driven by the increasing incidence of multi-organ failure, the growing geriatric population, the rising number of organ transplants and organ donors, and increasing initiatives to encourage organ donations. However, the high cost of organ transplantations and religious concerns in specific geographies are expected to limit market growth to a certain extent.

“The University of Wisconsin (UW) holds the market share in the solutions market.”

Based on the Solution, the segment is divided into UW, Custodial HTK, Perfadex and Other solutions (EuroCollins and Celsior). In 2019, the UW solution accounted for the highest share of 92.92 USD million in 2019. The UW solution is used for the flushing and storage of kidneys, liver, and pancreas. It was the first intracellular preservation medium, considered the gold standard for organ preservation. Paradox accounts for themost considerable CAGR in the forecast period of 2019-2024.

“Normothermic Machine Perfusion accounts for the highest CAGR in the forecast period.”

Normothermic machine perfusion marked the highest CAGRin the forecast period of 2019 to 2024. Normothermic perfusion is a technique that recreates the physiologic environment by maintaining average organ temperature and providing essential substrates for cellular metabolism, oxygenation, and nutrition. It is said to enhance the safety and efficacy of the organ and improve repair before transplantation. The normothermic technique is said to reduce the pro-inflammatory response in the liver and the risk of ischemic injuries while promoting graft regeneration. The possibility of long-term graft survival and reduced delayed graft functioning in organs of marginal quality (such as those from older donors) has made normothermic machine perfusion increasingly relevant.

Static cold storage and hypothermic machine perfusion are the other techniques involved in this segment.

“Kidneys holds the highest share in the segment by organ type.”

Kidneys accounts for a market share in the organ segment. Renal transplantation is considered the treatment of choice for patients with end-stage renal disease (ESRD) or kidney failure, diabetes,etc.are all cause for the growth of this segment. Other causes of ESRD in adult patients are polycystic kidney disease and glomerulonephritis. With the rising incidence of diabetes, the number of patients with ESRD or kidney failure is expected to increase, which will drive demand for kidney transplants. Moreover, improvements in graft survival and long-term graft function have made kidney transplantation a cost-effective alternative to dialysis. Major organs like Lungs, Liver, Kidney and Heart are a part of this segment.

“The Asia Pacific to witness the highest growth during the forecast period.”

Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2019–2024. The major factors driving the growth of the Asia Pacific market include favorable government initiatives, increased awareness in people and increased organ donations. Intensified public education, mobilization, and advancements in organ transplant technologies have improved the donation rate in China. In India, Rapid improvements in the country’s healthcare infrastructure have supported market growth while encouraging medical tourism. The willingness to donate organs in Japan has led to the improvement in organ donation despite religious issues. Other countries have initiative reimbursement programs, paired organ donation scheme with other patients within the country and across countries, have improved the growth of this market drastically.

Break of primary participants was as mentioned below:

  • By Company Type: Tier I: 50%, Tier II: 30%, Tier III: 20%
  • By Designation: C-Level Executives: 37%, Directors: 29%, Others: 34%
  • By Region: North America: 35%, Europe: 30%, Asia Pacific: 25%, RoW: 10%

XVIVO Perfusion AB (Sweden), Paragonix Technologies (US), Dr. Franz Kohler Chemie GMBH (Germany) are the leading players in the organ preservation market.

Research Coverage

This report studies the organ preservation market based on solution, technique, organ type, and region. The report also studies the different factors (such as drivers, restraints, and opportunities) affecting the market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets concerning their growth trends and forecasts the revenue of the market segments with respect to four central regions and respective countries.

Key Benefits of Buying the Report

This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the organ preservation market, and their drivers, restraints, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the organ preservation market.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : marketsandmarkets
More Reports
Title Price Buy Now

Telehealth Market by Component Software & Services (RPM, RTM), Application (Teleradiology, telestroke, teleICU), Hardware (Glucose Meters), End-User (Provider, Payer, Patient), Delivery Mode (On-Premise, Cloud) Trends & Global Forecast to 2025

“The telehealth market is projected to grow at a CAGR of 16.9% during the forecast period (2020–2025).” The global telehealth market is projected to reach USD 55.6 billion by 2025 from USD 25.5 billion in 2020, at a CAGR of 16.9 % during the forecast period. The key factors driving the growth of this market include the need to expand healthcare access, the growing prevalence of chronic diseases and conditions, a shortage of physicians, advancements in telecommunications, and government support and raising awareness. However, regional variations in regulations, fraud, and the use of social media for care providers will restrict the market growth during the forecast period. “The software & services segment will grow at the highest rate during the forecast period.” Base......
$4950

Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025

“The global biosimilars  market size is projected to register a CAGR of 24.7% during the forecast period.” The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. Growth in this industry is driven by the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. On the other hand, complexities in manufacturing restraining the market. “The monoclonal antibody segment is anticipated to grow at the fastest growth rate during the forecast period.” The biosimilars market by service is categorized into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept......
$5650

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020" provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020" provides an overview of Pre-Diabetes Impaired Glucose Tolerance Clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports ......
$2500

Schizoaffective Disorder Global Clinical Trials Review, H1, 2020

Schizoaffective Disorder Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Schizoaffective Disorder Global Clinical Trials Review, H1, 2020" provides an overview of Schizoaffective Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Schizoaffective Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020

Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020" provides an overview of Nasopharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Nasopharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500

Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020

Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020" provides an overview of Post Operative Nausea And Vomiting Clinical trials scenario. This report provides top line data relating to the clinical trials on Post Operative Nausea And Vomiting. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using ......
$2500

Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020

Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020" provides an overview of Seasonal Allergic Rhinitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Seasonal Allergic Rhinitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020" provides an overview of Chemotherapy Induced Nausea and Vomiting Clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Nausea and Vomiting. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Repo......
$2500

Cirrhosis Global Clinical Trials Review, H1, 2020

Cirrhosis Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Cirrhosis Global Clinical Trials Review, H1, 2020" provides an overview of Cirrhosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Cirrhosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy